{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:55:29Z","timestamp":1775429729576,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This real-world, non-interventional, retrospective cohort study evaluated the achievement rate of guideline-recommended target blood pressure (BP) and representative safety profile of the treatment incorporating sacubitril\/valsartan (Sac\/Val) in Japanese patients with essential hypertension. Data were collected from electronic health records from ~4700 clinics across Japan, covering ~11.4% of the nationwide population. Of the 1405 eligible patients, 1247 were included in the effectiveness analysis. The primary endpoint investigated the proportion of patients achieving the Japanese Society of Hypertension 2019\u2013recommended antihypertensive goals within 8 weeks of initial Sac\/Val administration (index date). Secondary endpoints included description of baseline characteristics and their relative contribution to BP goal attainment, description of prescription patterns, and safety. A total of 29.8% of patients achieved individual estimated BP goals, with significant mean reductions in systolic and diastolic BPs (\u221215.6\u2009mmHg and \u22126.1\u2009mmHg, respectively,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Patients aged \u226575 years, those with cerebrovascular disease, and those classified as Grade I hypertension were more likely to meet BP goals. Among patients with BP reduction of \u226510\u2009mmHg, the most common prescription pattern at index date was a combination of calcium channel blocker (CCB) and Sac\/Val, and a majority switched from CCB and angiotensin receptor blocker combination or were on CCB monotherapy. The most common signs of adverse events were hypotension and diuresis-related events, particularly during summer. The discontinuation rates following these signs were 1.0% and 0.8%. This real-world study demonstrated the clinical utility and representative safety profile of treatments involving Sac\/Val in Japanese patients with essential hypertension.\n                  <\/jats:p>","DOI":"10.1038\/s41440-025-02537-w","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T02:47:15Z","timestamp":1768358835000},"page":"1232-1244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of treatment strategies incorporating sacubitril\/valsartan on achievement of guideline-recommended blood pressure targets and representative safety outcomes"],"prefix":"10.1038","volume":"49","author":[{"given":"Tomohiro","family":"Katsuya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Nakatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Iekushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hiramitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2537_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/CIRCRESAHA.119.314991","volume":"124","author":"N Hirawa","year":"2019","unstructured":"Hirawa N, Umemura S, Ito S. Viewpoint on guidelines for treatment of hypertension in Japan. Circ Res. 2019;124:981\u20133.","journal-title":"Circ Res"},{"key":"2537_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41371-021-00534-3","volume":"38","author":"T Hisamatsu","year":"2024","unstructured":"Hisamatsu T, Miura K. Epidemiology and control of hypertension in Japan: a comparison with Western countries. J Hum Hypertens. 2024;38:469\u201376.","journal-title":"J Hum Hypertens"},{"key":"2537_CR3","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41440-021-00731-0","volume":"44","author":"E Asakura","year":"2021","unstructured":"Asakura E, Ademi Z, Liew D, Zomer E. Productivity burden of hypertension in Japan. Hypertens Res. 2021;44:1524\u201333.","journal-title":"Hypertens Res"},{"key":"2537_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47:1099\u2013102.","journal-title":"Hypertens Res"},{"key":"2537_CR5","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1038\/s41440-023-01414-8","volume":"46","author":"S Shibata","year":"2023","unstructured":"Shibata S. Hypertension paradox in Japan: the road ahead. Hypertens Res. 2023;46:2497\u20139.","journal-title":"Hypertens Res"},{"key":"2537_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2537_CR7","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41440-023-01366-z","volume":"46","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Chin K, Hatori N, Furuki T, Sakai H, Miyakawa M, et al. Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021, conducted in collaboration with Japan Medical Association Database of Clinical Medicine. Hypertens Res. 2023;46:2447\u201359.","journal-title":"Hypertens Res"},{"key":"2537_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","volume":"45","author":"H Rakugi","year":"2022","unstructured":"Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45:824\u201333.","journal-title":"Hypertens Res"},{"key":"2537_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1253\/circj.CJ-23-0174","volume":"88","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Long-term treatment with sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction- open-label extension of the PARALLEL-HF study. Circ J. 2023;88:43\u201352.","journal-title":"Circ J"},{"key":"2537_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/jch.13153","volume":"20","author":"DG Cheung","year":"2018","unstructured":"Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen CW, Zhang J. Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study. J Clin Hypertens. 2018;20:150\u20138.","journal-title":"J Clin Hypertens"},{"key":"2537_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jch.13437","volume":"21","author":"Y Huo","year":"2019","unstructured":"Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens. 2019;21:67\u201376.","journal-title":"J Clin Hypertens"},{"key":"2537_CR12","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.21037\/apm-22-503","volume":"11","author":"HX Wu","year":"2022","unstructured":"Wu HX, Liu KK, Li BN, Liu S, Jin JC. Efficacy and safety of sacubitril\/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2022;11:1811\u201325.","journal-title":"Ann Palliat Med"},{"key":"2537_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027612","volume":"12","author":"K Kario","year":"2023","unstructured":"Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Twenty-four-hour blood pressure-lowering efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension based on nocturnal blood pressure dipping status: a post hoc analysis of data from a randomized, double-blind multicenter study. J Am Heart Assoc. 2023;12:e027612.","journal-title":"J Am Heart Assoc"},{"key":"2537_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1253\/circj.CJ-23-0349","volume":"88","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and safety of sacubitril\/valsartan in Japanese patients with heart failure according to baseline systolic blood pressure- results from a subgroup analysis of the PARALLEL-HF study. Circ J. 2023;88:53\u201361.","journal-title":"Circ J"},{"key":"2537_CR15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","volume":"27","author":"H Tsutsui","year":"2021","unstructured":"Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al. JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail. 2021;27:1404\u201344.","journal-title":"J Card Fail"},{"key":"2537_CR16","unstructured":"M3 Inc. About M3. Accessed December 2024. https:\/\/corporate.m3.com\/en\/corporate\/."},{"key":"2537_CR17","doi-asserted-by":"crossref","unstructured":"Miyawaki A, Kitajima K, Iwata A, Sato D, Tsugawa Y. Physician characteristics associated with antiviral prescriptions for older adults with COVID-19 in Japan: an observational study. BMJ Open. 2024;14:e083342.","DOI":"10.1136\/bmjopen-2023-083342"},{"key":"2537_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285\u201392.","journal-title":"Hypertension"},{"key":"2537_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1253\/circrep.CR-24-0017","volume":"6","author":"T Horio","year":"2024","unstructured":"Horio T, Iwashima Y, Yoshiyama M, Fukuda D, Hasegawa T, Fujimoto K. Clinical benefit of sacubitril\/valsartan for hypertensive patients in daily practice and predictors of its antihypertensive effect. Circ Rep. 2024;6:248\u201354.","journal-title":"Circ Rep"},{"key":"2537_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","volume":"76","author":"K Kitagawa","year":"2019","unstructured":"Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke a randomized clinical trial and meta-analysis. JAMA Neurol. 2019;76:1309\u201318.","journal-title":"JAMA Neurol"},{"key":"2537_CR21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"2537_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","volume":"69","author":"B Williams","year":"2017","unstructured":"Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017;69:411\u201320.","journal-title":"Hypertension"},{"key":"2537_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/HJH.0000000000001219","volume":"35","author":"JG Wang","year":"2017","unstructured":"Wang JG, Yukisada K, Sibulo A Jr, Hafeez K, Jia Y, Zhang J. Efficacy and safety of sacubitril\/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens. 2017;35:877\u201385.","journal-title":"J Hypertens"},{"key":"2537_CR24","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1097\/00004872-199816110-00004","volume":"16","author":"R Sega","year":"1998","unstructured":"Sega R, Cesana G, Bombelli M, Grassi G, Stella ML, Zanchetti A, et al. Seasonal variations in home and ambulatory blood pressure in the PAMELA population. J Hypertens. 1998;16:1585\u201392.","journal-title":"J Hypertens"},{"key":"2537_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archinternmed.2008.512","volume":"169","author":"A Alp\u00e9rovitch","year":"2009","unstructured":"Alp\u00e9rovitch A, Lacombe JM, Hanon O, Dartigues JF, Ritchie K, Ducimeti\u00e8re P, et al. Relationship between blood pressure and outdoor temperature in a large sample of elderly individuals the three-city study. Arch Intern Med. 2009;169:75\u201380.","journal-title":"Arch Intern Med"},{"key":"2537_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/10641960902929479","volume":"32","author":"T Kimura","year":"2010","unstructured":"Kimura T, Senda S, Masugata H, Yamagami A, Okuyama H, Kohno T, et al. Seasonal blood pressure variation and its relationship to environmental temperature in healthy elderly Japanese studied by home measurements. Clin Exp Hypertens. 2010;32:8\u201312.","journal-title":"Clin Exp Hypertens"},{"key":"2537_CR27","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/HJH.0b013e32835465b5","volume":"30","author":"S Lewington","year":"2012","unstructured":"Lewington S, Li LM, Sherliker P, Guo Y, Millwood I, Bian Z, et al. Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse regions of China: the China Kadoorie Biobank. J Hypertens. 2012;30:1383\u201391.","journal-title":"J Hypertens"},{"key":"2537_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/hr.2015.96","volume":"38","author":"GS Stergiou","year":"2015","unstructured":"Stergiou GS, Myrsilidi A, Kollias A, Destounis A, Roussias L, Kalogeropoulos P. Seasonal variation in meteorological parameters and office, ambulatory and home blood pressure: predicting factors and clinical implications. Hypertens Res. 2015;38:869\u201375.","journal-title":"Hypertens Res"},{"key":"2537_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.amjmed.2014.02.037","volume":"127","author":"JJ Huang","year":"2014","unstructured":"Huang JJ, Sharda N, Bin Riaz I, Alpert JS. Summer syncope syndrome. Am J Med. 2014;127:787\u201390.","journal-title":"Am J Med"},{"key":"2537_CR30","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","volume":"73","author":"PL Myhre","year":"2019","unstructured":"Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73:1264\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"2537_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","volume":"73","author":"NE Ibrahim","year":"2019","unstructured":"Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 2019;73:1273\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"2537_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1517\/13543784.13.6.643","volume":"13","author":"G Boerrigter","year":"2004","unstructured":"Boerrigter G, Burnett JC. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs. 2004;13:643\u201352.","journal-title":"Expert Opin Investig Drugs"},{"key":"2537_CR33","doi-asserted-by":"publisher","unstructured":"Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. In: Schmidt HHHW, Hofmann F, Stasch J-P editor. cGMP: Generators, Effectors and Therapeutic Implications. Springer Berlin Heidelberg; Berlin, Heidelberg: 2009, p. 341\u201366 https:\/\/doi.org\/10.1007\/978-3-540-68964-5_15.","DOI":"10.1007\/978-3-540-68964-5_15"},{"key":"2537_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","volume":"69","author":"TD Wang","year":"2017","unstructured":"Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, et al. Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69:32\u201341.","journal-title":"Hypertension"},{"key":"2537_CR35","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(97)05189-1","volume":"350","author":"A Morimoto","year":"1997","unstructured":"Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734\u20137.","journal-title":"Lancet"},{"key":"2537_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jama.287.8.1003","volume":"287","author":"RS Vasan","year":"2002","unstructured":"Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D\u2019Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003\u201310.","journal-title":"JAMA"},{"key":"2537_CR37","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41440-021-00732-z","volume":"44","author":"K Narita","year":"2021","unstructured":"Narita K, Hoshide S, Kario K. Seasonal variation in blood pressure: current evidence and recommendations for hypertension management. Hypertens Res. 2021;44:1363\u201313.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02537-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:05:27Z","timestamp":1775426727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02537-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2537"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02537-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Honoraria and fees for promotional material: TK (Daiichi Sankyo Co. Ltd., Novartis Pharma K.K., CureApp, Inc.), SH (Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Bayer Yakuhin, Ltd.); Employment: FN, SE, KI, SH\u2019s family member (Novartis Pharma K.K.), YN, MM (Otsuka Pharmaceutical Co., Ltd.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}